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Abstract
Background: American Indians/Alaskan Natives have a high mortality associated with hepatitis C virus, yet treatment rates
are low. The ECHO (Extension for Community Healthcare Outcomes) model™, a videoconferencing technology for primary
care providers, is underutilized at Indian Health Service facilities.
Purpose: To ascertain Indian Health Service providers’ benefit of and barriers to utilizing hepatitis C virus TeleECHO clinics.
Methods: We electronically sent an Active Participant Survey to Indian Health Service providers utilizing hepatitis C virus
TeleECHO clinic and a Non-Participant Survey to other Indian Health Service providers interested in this clinic.
Results: In total, 100% of Active Participant Survey respondents perceive moderate to major benefit of hepatitis C virus
TeleECHO clinic in managing hepatitis C virus, and 67% of Non-Participant Survey respondents reported lack of administrative
time as the major barrier to utilizing this resource.
Conclusion: Indian Health Service providers participating in hepatitis C virus TeleECHO clinic perceive this resource as
highly beneficial, but widespread utilization may be impractical without allocating time for participation.
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Introduction
Chronic liver disease (CLD) is the fifth leading cause of
mortality among American Indians/Alaskan Natives (AI/
ANs).1 National hepatitis C virus (HCV) surveillance in this
population has been limited, but recent available data are
concerning. HCV is the second leading cause of CLD in the
Southwestern US AIs.2 Native HCV-infected patients are
twice as likely to die from HCV-related events than nonnative patients in the United States. In 2011, AI/ANs had the
highest mortality rates of persons with HCV by race/ethnicity (10.6 per 100,000 population).3 Elevated rates of comorbidities, such as type 2 diabetes and alcoholic steatohepatitis,
may contribute to this disparity in disease progression.
Despite increased identification of HCV in AI/ANs as a
significant cause of liver disease and mortality, treatment
rates are low. In a retrospective cohort study of AI/ANs in

Alaska, treatment was initiated in 14 (10%) of 146 patients
in 2007.4 In two North Dakota medical facilities, 22 (18%) of
124 AI/ANs received HCV treatment, with lack of access to
specialists cited as a common barrier to treatment.5 Lack of
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access to treatment has also been cited as a barrier to screening AI/ANs for HCV.6
The Indian Health Service (IHS), an agency within the
Department of Health and Human Services, provides federal health services to approximately 2.2 million of the
nation’s estimated 3.7 million AI/ANs. The Navajo Area
Indian Health Service (NAIHS), one of 12 IHS regional
administrative units, is responsible for health services to AIs
in portions of Arizona, New Mexico, and Utah. IHS primary
care clinics and hospitals are located mainly in rural locations, without ready access to subspecialty care. Historically,
primary care clinicians in rural areas have rarely offered
treatment for HCV.7,8
Project ECHO® (Extension for Community Healthcare
Outcomes) was developed at the University of New Mexico
Health Sciences Center (UNMHSC) to increase access to
specialty care for patients with chronic and complex conditions in rural and underserved areas of New Mexico. The
ECHO model™ connects academic medical center specialists weekly with primary care clinicians over a videoconferencing network (TeleECHO clinics). A recent prospective
cohort study found equivalent rates of sustained viral
response (cure) between patients treated at the UNMHSC
HCV clinic and those treated by primary care clinicians
using the ECHO model.9
HCV TeleECHO clinics convene weekly. Over the past
2 years, significant efforts have been made to provide HCV
ECHO services to IHS facilities, including networking with
IHS primary care providers and subspecialists during site
visits and IHS conferences. In March 2013, a monthly IHSexclusive HCV TeleECHO clinic was established specifically for IHS providers.
Recruitment efforts have been most effective in NAIHS
facilities. However, IHS participation is still low. Since 2010,
only three out of six NAIHS hospitals and one out of seven
NAIHS health centers have utilized UNM HCV TeleECHO
clinic.
The goal of this study was to delineate IHS-specific barriers to utilizing the ECHO model by surveying IHS providers
interested in treating HCV. We hypothesized that lack of
technical support, and limited clinic or administrative time
are impeding participation in TeleECHO clinics.

Methods
The UNMHSC Office of Human Research Protections
Office reviewed and approved the full protocol. IHS providers who, within the last year, had ever shown interest in treating HCV by attending any HCV TeleECHO clinic were
recruited via email. The introductory email describing the
project included a link to an electronic survey. The survey
was available from 15 May to 15 September 2014. Two general reminder emails were sent to all IHS providers during
the study period, and individual emails to enhance recruitment were also sent.
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IHS providers who had been mentored to treat at least one
patient with HCV ECHO were directed to the Active
Participant Survey (APS), while the rest were directed to the
Non-Participant Survey (NPS). Both surveys included items
regarding characteristics of providers, IHS facility, and total
number of HCV patients on providers’ panels. Items specific
to NPS included barriers to becoming an HCV treater, while
items specific to APS included benefits to utilizing HCV
TeleECHO. Both surveys had open-ended questions, where
providers could elaborate on their responses.
Survey responses were collected and analyzed using
Gravic Remark Web Survey Version 5 and Excel. Fisher’s
exact test was used to compare between-group respondent
characteristics, with a significance level of 0.05. Medians
and quartiles were calculated to describe Likert-type scales.
Due to the limited scope of this study, a power analysis was
not conducted. All survey responses were presented anonymously to the study investigators.

Results
In all, 38 (53%) of the 72 recipients contacted agreed to participate in the study. A total of 25 (66%) respondents filled
out the NPS, and 13 (34%) respondents filled out the APS.
Six respondents were noted to be non-providers and were
dropped from the analysis, resulting in 20 (63%) NPS
respondents and 12 (38%) APS respondents. In total, 15 IHS
facilities were represented, from eight IHS regional areas.
Seven respondents did not disclose their facility. There were
significantly more NPS than APS respondents with
6–20 years of active clinical practice (p value = 0.014). Of the
11 APS respondents who had personally treated patients
within the past year for HCV, 10 (91%) had co-managed
100% of these patients with a TeleECHO clinic. A total of
75% of APS respondents participated in UNM HCV
TeleECHO clinic; the rest participated in the University of
Washington HCV TeleECHO clinic.
APS and NPS respondents were similar regarding medical professions and HCV patient panel size. Most respondents had five or more HCV patients on their panels, with six
(32%) NPS respondents and five (42%) APS respondents
reporting >30 HCV patients on their panels (Table 1). More
NPS than APS respondents (57% versus 18%, respectively)
had Infectious Disease (ID) or Gastroenterology (GI) subspecialists at their facilities, though this difference was not
statistically significant.
While 13 (68%) of NPS respondents reported interest in
potentially presenting patients to TeleECHO clinic, they
consistently reported lack of administrative time as the most
significant barrier (Table 2). In the open-ended questions,
both NPS respondents (67%) and APS respondents (50%)
reported lack of time to attend TeleECHO clinic as a major
barrier to participation.
Feedback regarding the benefits of participating in HCV
TeleECHO clinic was consistently positive. In total, 100% of
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Table 1. Characteristics of Survey Respondents.
Number of participants

IHS sites
IHS regional areas
ID/GI on site
IHS facility reported
Profession
Physician
Pharmacist
PA/NP
Years in active clinical practice
0–5 years
6–20 years
>20 years
Years out of training
0–5 years
6 or more years
Number of HCV patients on panel
<5
5–30
>30
No response

Active Participant Survey

Non-Participant Survey

p value

12

*

20

*

5
2
11

18%
92%

5
8
14

57%
70%

0.1

5
4
3

42%
33%
25%

12
6
2

60%
30%
10%

0.47
1
0.34

10
0
2

83%
0%
17%

10
8
2

50%
40%
10%

0.08
0.01
0.62

10
2

83%
17%

9
11

45%
55%

0.06

2
5
5
0

17%
42%
42%
0%

8
5
6
1

42%
26%
32%

0.24
0.45
0.71

IHS: Indian Health Service; ID/GI: Infectious Disease/Gastroenterology subspecialist; PA/NP: Physician Assistant/Nurse Practitioner; HCV: hepatitis C virus.
*Unknowns excluded from denominator.

Table 2. Non-Participant Survey (NPS) Respondents: Barriers to Using HCV ECHO.

Lack of technology or institutional support to
implement software
Lack of administrative time to participate in HCV
TeleECHO clinic
I am concerned about the legal ramifications of
treating HCV, regardless of whether the patient is
co-managed with the HCV TeleECHO clinic
Lack of clerical support to gather data for patient
presentations to HCV TeleECHO clinic
There is an infectious disease subspecialist at
my IHS site
I don’t think TeleECHO is an adequate method of
co-managing treatment
HCV TeleECHO clinic is not sensitive to the specific
needs of my native patients

Not a
barrier (1)

Minor
barrier (2)

Moderate
barrier (3)

Major
barrier (4)

N/Aa

Median

Quartile
(Q1–Q3)b

8
42%
1
6%
17
89%

1
5%
1
6%
2
11%

7
37%
4
22%
0
0%

3
16%
12
67%
0
0%

1

3

(1, 3)

2

4

(3, 4)

1

1

(1, 1)

6
33%
8
67%
16
94%
16
89%

4
22%
2
17%
1
6%
2
11%

5
28%
1
8%
0
0%
0
0%

3
17%
1
8%
0
0%
0
0%

2

2

(1, 3)

8

1

(1, 2)

3

1

(1, 1)

2

1

(1, 1)

HCV: hepatitis C virus.
aN/A were not included in the calculation of median and quartiles.
bQ1 = 25th percentile; Q3 = 75th percentile.

APS respondents rated being well-informed, self efficacy,
access to expertise, collegiality, and decreased professional
isolation as moderate to major benefits (Table 3), and 50% of
APS respondents stated they would not treat HCV without
regular participation in this clinic.

Discussion
This is the first HCV ECHO survey focusing on IHS providers. Most providers (68%) reported having multiple (five or
more) HCV patients on their panels, indicating the relevance
of HCV treatment to the survey respondents.
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Table 3. Active Participant Survey (APS) Respondents: Benefits to Using HCV ECHO.

Being well-informed about symptoms in HCV
Self-efficacy: belief in my ability to manage and treat HCV
patients
Access to expertise in behavioral/mental health resources
Access to expertise in pharmacy
Collegial discussion with peers about HCV patients

Not a
benefit

Minor
benefit

0
0%
0
0%
0
0%
0
0%
0
0%

0
0%
0
0%
0
0%
0
0%
0
0%

Moderate
benefit

Major
benefit

N/Aa

Median

Quartile
(Q1–Q3)b

2
17%
4
36%
4
33%
3
27%
1
8%

10
83%
7
64%
7
58%
8
73%
11
92%

0

4

(4, 4)

1

4

(3, 4)

1

4

(3, 4)

1

4

(3.5, 4)

0

4

(4, 4)

HCV: hepatitis C virus.
aN/A were not included in the calculation of median and quartiles.
bQ1 = 25th percentile; Q3 = 75th percentile.

Lack of administrative time to devote to HCV ECHO participation was consistently reported as a major barrier in both
the quantitative and free form sections of the surveys. IHS
providers described a need for allocated time set aside to
take part in TeleECHO clinics, which is not currently provided in many of their facilities, as well as administrative
assistance. Providers must not only be available to present
patients weekly via videoconference but also regularly provide medical history and laboratory results prior to their
presentations.
Our results are consistent with other HCV ECHO provider surveys, which reported significant improvement in
providers’ ability to manage and treat HCV patients.10,11
Results also suggest that a large portion of participants who
utilized the ECHO model to treat HCV (50% in this study)
would not be treating HCV otherwise. This is consistent with
a recent analysis of Centers for Disease Control and Prevention
(CDC)-funded programs in Utah and Arizona, modeled on
HCV Project ECHO. Nearly all (93%) of participating providers had no prior experience treating HCV, but after implementation of these programs, 129 (46%) of the HCV-infected
patients presented in TeleECHO clinics received antiviral
treatment.12
APS respondents were more likely than NPS respondents
to have 0–5 years of active clinical practice, (p value = 0.014),
and to have finished training within the last 5 years (p
value = 0.06). This suggests that recently trained providers
are more likely to utilize HCV TeleECHO clinic. The presence of ID or GI subspecialists at an IHS facility may also be
associated with lower TeleECHO clinic utilization, but in
this small study, the between-group difference did not reach
statistical significance.
The survey results are limited by the inherent biases associated with self-reporting and the limited number of respondents. We were unable to determine whether responses were
site-specific or HCV TeleECHO clinic–specific, given the
low survey response rate in most facilities. The small group

of APS respondents also limited between-group analyses.
However, in light of known low IHS provider participation,
there were a broad number of facilities represented in this
analysis, and one major barrier to TeleECHO clinic participation was consistently reported.
Currently, there is scant literature regarding treatment of
HCV in AI/ANs, particularly using videoconferencing technology. Further studies to determine how the ECHO model
could best be utilized by IHS facilities are needed. IHS providers utilizing HCV TeleECHO clinic perceive major benefit from this resource, but, practically, increased participation
requires either TeleECHO-dedicated provider time or administrative support.
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